109,555 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Purchased by EAM Investors LLC

EAM Investors LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 109,555 shares of the company’s stock, valued at approximately $451,000.

A number of other institutional investors also recently bought and sold shares of ELDN. ADAR1 Capital Management LLC acquired a new stake in Eledon Pharmaceuticals during the 4th quarter worth about $66,000. Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals in the fourth quarter worth about $82,000. Kera Capital Partners Inc. purchased a new position in Eledon Pharmaceuticals during the fourth quarter worth approximately $106,000. Charles Schwab Investment Management Inc. lifted its position in shares of Eledon Pharmaceuticals by 100.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company’s stock valued at $124,000 after buying an additional 15,000 shares in the last quarter. Finally, Barclays PLC purchased a new position in Eledon Pharmaceuticals during the fourth quarter valued at $288,000. 56.77% of the stock is owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Price Performance

NASDAQ:ELDN opened at $2.99 on Friday. The firm has a market capitalization of $179.05 million, a price-to-earnings ratio of -1.49 and a beta of 0.66. Eledon Pharmaceuticals, Inc. has a 1-year low of $1.55 and a 1-year high of $5.54. The company’s 50-day moving average is $3.63 and its two-hundred day moving average is $3.93.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the prior year, the business earned ($1.00) EPS. As a group, equities analysts anticipate that Eledon Pharmaceuticals, Inc. will post -0.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).